|Title:||Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in Taiwan||Authors:||FANG-JU LIN
Huey-Herng Sheu, Wayne
Inocencio, Timothy J
|Keywords:||Coronary artery disease; Cost-effectiveness analysis; Low-density lipoprotein cholesterol; Secondary prevention; Statin;Coronary artery disease; Cost-effectiveness analysis; Low-density lipoprotein cholesterol; Secondary prevention; Statin||Issue Date:||May-2020||Publisher:||ELSEVIER TAIWAN||Journal Volume:||119||Journal Issue:||5||Start page/Pages:||907||Source:||Journal of the Formosan Medical Association = Taiwan yi zhi||Abstract:||
The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70-100 mg/dL in Taiwan could be cost-effective.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/516779||ISSN:||0929-6646||DOI:||10.1016/j.jfma.2020.01.010||SDG/Keyword:||atorvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; pitavastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; Article; cardiac patient; cerebrovascular accident; cohort analysis; coronary artery disease; cost effectiveness analysis; drug cost; drug use; gross national product; health care cost; health status; heart infarction; human; incidence; major clinical study; Markov chain; mortality rate; probability; quality adjusted life year; recurrent disease; secondary prevention; sensitivity analysis; Taiwan; coronary artery disease; cost benefit analysis; economics; epidemiology; secondary prevention; Cholesterol, LDL; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Taiwan
|Appears in Collections:||臨床藥學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.